People's Understanding of Verbal Risk Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to 65-Year-Olds in England.

Abstract:

INTRODUCTION:Evidence suggests the current verbal risk descriptors used to communicate side effect risk in patient information leaflets (PILs) are overestimated. OBJECTIVES:The aim was to establish how people understand the verbal risk descriptors recommended for use in PILs by the European Commission (EC), and alternative verbal risk descriptors, in the context of mild and severe side effects. METHODS:A cross-sectional online survey was carried out by a market research company recruiting participants aged between 18 and 65 years living in England. Data were collected between 18 March and 1 April 2016. Participants were given a hypothetical scenario regarding the risk of mild or severe medication side effects and asked to estimate how many out of 10,000 people would be affected for each of the verbal risk descriptors being tested. RESULTS:A total of 1003 participants were included in the final sample. The risks conveyed by the EC recommended verbal risk descriptors were greatly overestimated by participants. Two distinct distributions were apparent for participant estimates of side effect risks: those for 'high risk' verbal descriptors (e.g. 'common', 'likely', 'high chance') and those for 'low risk' verbal descriptors (e.g. 'uncommon', 'unlikely', 'low chance'). Within these two groups, the distributions were near to identical regardless of what adverb (e.g. very, high, fair) or adjective (e.g. common, likely, chance) was used. The EC recommended verbal risk descriptors were more likely to be understood in accordance with their intended meanings when describing severe side effects. Very few demographic or psychological factors were consistently associated with how well participants understood the EC recommended verbal risk descriptors. DISCUSSION:The current verbal risk descriptors used in PILs are ineffective at best and misleading at worst. Discontinuing the use of verbal risk descriptors would limit the likelihood of people overestimating the risk of side effects.

journal_name

Drug Saf

journal_title

Drug safety

authors

Webster RK,Weinman J,Rubin GJ

doi

10.1007/s40264-017-0542-1

subject

Has Abstract

pub_date

2017-08-01 00:00:00

pages

743-754

issue

8

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-017-0542-1

journal_volume

40

pub_type

杂志文章
  • Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis.

    abstract::Intranasal corticosteroids and intranasal antihistamines are efficacious topical therapies in the treatment of allergic rhinitis. This review addresses their relative roles in the management of this disease, focusing on their safety and tolerability profiles. The intranasal route of administration delivers drug direct...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326120-00003

    authors: Salib RJ,Howarth PH

    更新日期:2003-01-01 00:00:00

  • Erice Call for Change: Utilising Patient Experiences to Enhance the Quality and Safety of Healthcare.

    abstract::This 'Erice Call for Change' is a report from a group of experts, patients and patient representatives who met in Erice in September 2019 following previous similar meetings after the original Erice Declaration (1996). The aim of the meeting was to discuss the challenge of causal complexity and individual variation in...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00919-2

    authors: Rocca E,Anjum RL

    更新日期:2020-06-01 00:00:00

  • Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

    abstract::Data from basic science and clinical studies suggest that hydroxyurea (hydroxycarbamide)-based regimens are effective treatment options for patients with HIV at various stages of disease. In vitro studies of HIV-infected lymphocytes have shown that hydroxyurea: (i) inhibits viral DNA synthesis; (ii) synergistically in...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326090-00002

    authors: Lisziewicz J,Foli A,Wainberg M,Lori F

    更新日期:2003-01-01 00:00:00

  • Poisoning by thallium. A study of five cases.

    abstract::Thallium poisoning seldom occurs in Spain. This article reports 5 cases of thallium poisoning, of which 4 of the patients belonged to the same family. The cases occurred in or near Granada between 1985 and 1987. The symptoms were initially gastrointestinal (vomiting, abdominal pain, gastrointestinal haemorrhage, etc.)...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199005050-00006

    authors: Villanueva E,Hernandez-Cueto C,Lachica E,Rodrigo MD,Ramos V

    更新日期:1990-09-01 00:00:00

  • Immunisation and type 1 diabetes mellitus: is there a link?

    abstract::Recent evidence from animal studies has raised the possibility that immunisation by vaccines can influence the pathogenesis of type I (insulin-dependent) diabetes mellitus. In non-obese diabetic mice and biobreeding rats, complete Freund's adjuvant and bacillus Calmette-Guérin (BCG) vaccine have successfully been used...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199920030-00001

    authors: Hiltunen M,Lönnrot M,Hyöty H

    更新日期:1999-03-01 00:00:00

  • Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.

    abstract:INTRODUCTION:Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators and biosimilars) are limited. In light of current debate about interchangeability, prescribers, some patient groups and decision makers are calling for additional post-marketing evidence...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00845-y

    authors: Belleudi V,Trotta F,Addis A,Ingrasciotta Y,Ientile V,Tari M,Gini R,Pastorello M,Scondotto S,Cananzi P,Traversa G,Davoli M,Trifirò G,Italian Biosimilar Network (ItaBioNet).

    更新日期:2019-12-01 00:00:00

  • Vancomycin-Induced Thrombocytopenia: A Narrative Review.

    abstract::Thrombocytopenia has been reported as an adverse reaction of numerous drugs. Vancomycin is often overlooked as a culprit but has been associated with several cases of thrombocytopenia that were not well described in the literature. A literature search was conducted to find reports of thrombocytopenia induced by vancom...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0469-y

    authors: Mohammadi M,Jahangard-Rafsanjani Z,Sarayani A,Hadjibabaei M,Taghizadeh-Ghehi M

    更新日期:2017-01-01 00:00:00

  • Improving follow-up rates in spontaneous adverse drug reaction reporting: effectiveness of a targeted letter used by a regional centre in the UK.

    abstract:BACKGROUND:Spontaneous reports of suspected adverse drug reactions to regulatory bodies and market authorization holders are important in pharmacovigilance. Follow-up information, which can be difficult to obtain, is often required from reporters; therefore, we developed targeted follow-up letters that we hoped would m...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11318940-000000000-00000

    authors: Anton C,Cox AR,Ferner RE

    更新日期:2009-01-01 00:00:00

  • Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

    abstract::The new generation fluoroquinolones -- sparfloxacin, levofloxacin, grepafloxacin and trovafloxacin -- have been designed to respond to the clinical need for extended antimicrobial cover in the face of increasing global microbial resistance. Their main focus is in the treatment of respiratory infections, particularly t...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921020-00005

    authors: Lode H

    更新日期:1999-08-01 00:00:00

  • Association between leukotriene-modifying agents and suicide: what is the evidence?

    abstract::The US FDA has issued safety alerts and required manufacturers of leukotriene-modifying agents (LTMAs), including montelukast, zafirlukast and zileuton, to include suicide and neuropsychiatric events as a precaution in the drug label. This paper reviews the existing evidence on the potential association between the LT...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11587260-000000000-00000

    authors: Schumock GT,Lee TA,Joo MJ,Valuck RJ,Stayner LT,Gibbons RD

    更新日期:2011-07-01 00:00:00

  • Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals.

    abstract:BACKGROUND:In the UK, spontaneous reporting of suspected adverse drug reactions (ADRs) by healthcare professionals has been in operation since 1964 through the Yellow Card Scheme (YCS). From 2005, patients themselves have been able to submit Yellow Card reports. OBJECTIVE:To compare patient characteristics, suspected ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11536510-000000000-00000

    authors: McLernon DJ,Bond CM,Hannaford PC,Watson MC,Lee AJ,Hazell L,Avery A,Yellow Card Collaboration.

    更新日期:2010-09-01 00:00:00

  • Drug treatment of depression in HIV-positive patients : safety considerations.

    abstract::Safe and effective treatment of major depression, one of the most common comorbid conditions in individuals infected with HIV, significantly lowers morbidity and mortality from HIV disease. However, optimal treatment of both conditions is complicated by interactions between the disease processes as well as the pharmac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200528090-00002

    authors: Pieper AA,Treisman GJ

    更新日期:2005-01-01 00:00:00

  • Heart failure induced by non-cardiac drugs.

    abstract::Although heart failure is predominantly caused by cardiovascular conditions such as hypertension, coronary heart disease and valvular heart disease, it can also be an adverse reaction induced by drug therapy. In addition, some drugs have the propensity to adversely affect haemodynamic mechanisms in patients with an al...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629070-00003

    authors: Slørdal L,Spigset O

    更新日期:2006-01-01 00:00:00

  • Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.

    abstract:INTRODUCTION:The use of mobile apps is increasing in medicine. In pharmacovigilance, mobile apps may help to increase adverse drug reaction reporting and improve the communication of safety issues. The Toulouse University Pharmacovigilance Center has developed VigiBIP®, a free smartphone app available on Android and Ap...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0630-2

    authors: Montastruc F,Bagheri H,Lacroix I,Damase-Michel C,Chebane L,Rousseau V,Jouanjus E,Lapeyre-Mestre M,Durrieu G,Montastruc JL

    更新日期:2018-05-01 00:00:00

  • Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.

    abstract::Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the target of new biologic treatments for patients with eosinophilic asthma. Given the central role of interleukin (IL)-5 in the eosinophil lifecycle, several therapies directed against the IL-5 pathway have been developed, including...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-020-00926-3

    authors: Jackson DJ,Korn S,Mathur SK,Barker P,Meka VG,Martin UJ,Zangrilli JG

    更新日期:2020-05-01 00:00:00

  • Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.

    abstract:BACKGROUND:While cases of amyotrophic lateral sclerosis (ALS) or ALS-like conditions have arisen in apparent association with HMG-CoA reductase inhibitors ('statins') and/or other lipid-lowering drugs (collectively termed 'statins' in this paper for brevity), additional information is needed to understand whether the c...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932080-00004

    authors: Golomb BA,Kwon EK,Koperski S,Evans MA

    更新日期:2009-01-01 00:00:00

  • Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

    abstract::The purpose of this review is to assess the benefits and risks associated with the use of the ketolide antibacterial telithromycin, currently licensed for the treatment of adults with mild to moderate community-acquired pneumonia (CAP). Telithromycin is active against both the major (Streptococcus pneumoniae, Haemophi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200831070-00002

    authors: Brown SD

    更新日期:2008-01-01 00:00:00

  • A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database.

    abstract:BACKGROUND:The detection of new drug safety signals is of growing importance with ever more new drugs becoming available and exposure to medicines increasing. The task of evaluating information relating to safety lies with national agencies and, for international data, with the World Health Organization Programme for I...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200023060-00004

    authors: Lindquist M,Ståhl M,Bate A,Edwards IR,Meyboom RH

    更新日期:2000-12-01 00:00:00

  • Patient Reporting in the EU: Analysis of EudraVigilance Data.

    abstract:INTRODUCTION:New pharmacovigilance legislation was adopted in the EU in 2010 and became operational in July 2012. The legislation placed an obligation on all national competent authorities (NCAs) and marketing authorisation holders (MAHs) to record and report cases of suspected adverse drug reactions (ADRs) received fr...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0534-1

    authors: Banovac M,Candore G,Slattery J,Houÿez F,Haerry D,Genov G,Arlett P

    更新日期:2017-07-01 00:00:00

  • Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link?

    abstract::Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed to women of child-bearing age. Three case series highlight the possibility of a link between NSAIDs and reversible infertility. The pharmacological target of NSAIDs is cyclo-oxygenase (COX), which catalyses the first rate-limiting step in the prod...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225080-00001

    authors: Stone S,Khamashta MA,Nelson-Piercy C

    更新日期:2002-01-01 00:00:00

  • The case-population study design: an analysis of its application in pharmacovigilance.

    abstract:BACKGROUND:The case-population approach or population-based case-cohort approach is derived from the case-control design and consists of comparing past exposure to a given risk factor in subjects presenting a given disease or symptom (cases) with the exposure rate to this factor in the whole cohort or in the source pop...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11592140-000000000-00000

    authors: Théophile H,Laporte JR,Moore N,Martin KL,Bégaud B

    更新日期:2011-10-01 00:00:00

  • Community Pharmacists' Views and Experiences with ADR Reporting for Complementary Medicines: A Qualitative Study in New Zealand.

    abstract:INTRODUCTION:Detecting signals of safety concerns associated with complementary medicines (CMs) relies on spontaneous reports submitted by health professionals and patients/consumers. Community pharmacists are well placed to identify and report suspected adverse drug reactions (ADRs) associated with CMs, but pharmacist...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00980-x

    authors: Barnes J,Butler R

    更新日期:2020-11-01 00:00:00

  • Managing Risks with Immune Therapies in Multiple Sclerosis.

    abstract::Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory and immunosuppressant disease-modifying therapies for multiple sclerosis (MS) have been developed. They have all shown positive effects on clinical endpoints such as relapse rate and disease progression and are a heteroge...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0782-8

    authors: Förster M,Küry P,Aktas O,Warnke C,Havla J,Hohlfeld R,Mares J,Hartung HP,Kremer D

    更新日期:2019-05-01 00:00:00

  • Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology.

    abstract::Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematological malignancies (T-cell lymphomas and multiple myeloma). However, they are not as effective in solid tumours. Five agents are currently appr...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0773-9

    authors: Shah RR

    更新日期:2019-02-01 00:00:00

  • Carbamazepine overdose. Features of 33 cases.

    abstract::Review of the medical records of 2 major adult teaching hospitals for a 4-year period revealed 33 instances of carbamazepine overdose. These patients had a mean age of 30 years and 58% were known epileptics. They ingested a mean of 12g carbamazepine (range 1.6 to 45g), with 51% of cases involving other drugs, particul...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199308010-00010

    authors: Seymour JF

    更新日期:1993-01-01 00:00:00

  • Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

    abstract:BACKGROUND:Psoriasis is a chronic autoimmune disease characterized by infiltration of the dermis and epidermis by activated T cells and the hyperproliferation and abnormal differentiation of keratinocytes. It is a life-long disease with alternating periods of remission and recurrence. Efalizumab is a humanized, recombi...

    journal_title:Drug safety

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00002018-200831080-00008

    authors: Hamilton T,Menter A,Caro I,Compton P,Sobell J,Papp KA

    更新日期:2008-01-01 00:00:00

  • A risk-benefit assessment of therapies for Lennox-Gastaut syndrome.

    abstract::The treatment of Lennox-Gastaut syndrome has been improved for some patients by the introduction of adjunctive therapy with newer anticonvulsants such as lamotrigine and topiramate and the availability of vagal nerve stimulation and the re-emergence of the use of the ketogenic diet in recent years. The place of standa...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200022060-00005

    authors: Schmidt D,Bourgeois B

    更新日期:2000-06-01 00:00:00

  • Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial.

    abstract::Antiplatelet therapy is universally recommended for the prevention of recurrent events in patients with noncardioembolic ischaemic stroke or transient ischaemic attack (TIA), acute and chronic coronary artery disease, or peripheral arterial disease. However, choosing which antiplatelet agents to use in these situation...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200831060-00001

    authors: Ruland S

    更新日期:2008-01-01 00:00:00

  • Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease.

    abstract::Benzodiazepine drugs have been shown to suppress respiratory function in patients with chronic obstructive pulmonary disease (COPD). We designed a placebo-controlled crossover study to compare the effects of a new benzodiazepine, estazolam ('ProSom'), with those of flurazepam ('Dalmane') on cardiopulmonary function in...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00002018-199207020-00006

    authors: Cohn MA,Morris DD,Juan D

    更新日期:1992-03-01 00:00:00

  • Antihyperlipidaemic agents. Drug interactions of clinical significance.

    abstract::The available antihyperlipidaemic drugs are generally safe and effective, and major systemic adverse effects are uncommon. However, because of their complex mechanisms of action, careful monitoring is required to identify and correct potential drug interactions. Bile acid sequestrants are the most difficult of these a...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199411050-00002

    authors: Farmer JA,Gotto AM Jr

    更新日期:1994-11-01 00:00:00